The 2023-2028 Outlook for Birth Control Clinics in China

This study covers the latent demand outlook for birth control clinics across the regions of China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Chongqing, Shanghai, and Tianjin), special administrative regions (Hong Kong a...

8/16/2022 | China Outlook 2023

The 2023-2028 Outlook for Biosimilars in China

This study covers the latent demand outlook for biosimilars across the regions of China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Chongqing, Shanghai, and Tianjin), special administrative regions (Hong Kong and Macau),...

8/16/2022 | China Outlook 2023

The 2023-2028 Outlook for Biopreservation in China

This study covers the latent demand outlook for biopreservation across the regions of China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Chongqing, Shanghai, and Tianjin), special administrative regions (Hong Kong and Mac...

8/16/2022 | China Outlook 2023

The 2023-2028 Outlook for Biosimilars and Follow-on Biologics Drugs in China

This study covers the latent demand outlook for biosimilars and follow-on biologics drugs across the regions of China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Chongqing, Shanghai, and Tianjin), special administrative ...

8/16/2022 | China Outlook 2023

The 2023-2028 Outlook for Biophotonics in China

This study covers the latent demand outlook for biophotonics across the regions of China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Chongqing, Shanghai, and Tianjin), special administrative regions (Hong Kong and Macau)...

8/16/2022 | China Outlook 2023

The 2023-2028 Outlook for Bipolar Disorder Treatments in China

This study covers the latent demand outlook for bipolar disorder treatments across the regions of China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Chongqing, Shanghai, and Tianjin), special administrative regions (Hong ...

8/16/2022 | China Outlook 2023

The 2023-2028 Outlook for Biostimulants in China

This study covers the latent demand outlook for biostimulants across the regions of China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Chongqing, Shanghai, and Tianjin), special administrative regions (Hong Kong and Macau...

8/16/2022 | China Outlook 2023

The 2023-2028 Outlook for Biological Imaging Reagents in China

This study covers the latent demand outlook for biological imaging reagents across the regions of China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Chongqing, Shanghai, and Tianjin), special administrative regions (Hong ...

8/16/2022 | China Outlook 2023

The 2023-2028 Outlook for Biologic Vasculitis Treatments in China

This study covers the latent demand outlook for biologic vasculitis treatments across the regions of China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Chongqing, Shanghai, and Tianjin), special administrative regions (Ho...

8/16/2022 | China Outlook 2023

The 2023-2028 Outlook for Biodegradable Cutlery in China

This study covers the latent demand outlook for biodegradable cutlery across the regions of China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Chongqing, Shanghai, and Tianjin), special administrative regions (Hong Kong a...

8/16/2022 | China Outlook 2023

This study covers the latent demand outlook for birth control clinics across the regions of China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Chongqing, Shanghai, and Tianjin), special administrative regions (Hong Kong and Macau), and Taiwan (all hereafter referred to as "regions"). Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 1,100 cities in China. For each major city in question, the percent share the city is of the region and of China is reported. Each major city is defined as an area of "economic population", as opposed to the demographic population within a legal geographic boundary. For many cities, the economic population is much larger that the population within the city limits this is especially true for the cities of the Western regions. For the coastal regions, cities which are close to other major cities or which represent, by themselves, a high percent of the regional population, actual city-level population is closer to the economic population (e.g. in Beijing). Based on this "economic" definition of population, comparative benchmarks allow the reader to quickly gauge a city's marketing and distribution value vis-à-vis others. This exercise is quite useful for persons setting up distribution centers or sales force strategies. Using econometric models which project fundamental economic dynamics within each region and city of influence, latent demand estimates are created for birth control clinics. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of birth control clinics as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Florida Institute for Reproductive Medicine, Nevada Center for Reproductive Medicine, NYU School of Medicine, Southern California Home Financing Authority,, and Weill Cornell Medicine Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

8/16/2022

This study covers the latent demand outlook for biosimilars across the regions of China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Chongqing, Shanghai, and Tianjin), special administrative regions (Hong Kong and Macau), and Taiwan (all hereafter referred to as "regions"). Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 1,100 cities in China. For each major city in question, the percent share the city is of the region and of China is reported. Each major city is defined as an area of "economic population", as opposed to the demographic population within a legal geographic boundary. For many cities, the economic population is much larger that the population within the city limits this is especially true for the cities of the Western regions. For the coastal regions, cities which are close to other major cities or which represent, by themselves, a high percent of the regional population, actual city-level population is closer to the economic population (e.g. in Beijing). Based on this "economic" definition of population, comparative benchmarks allow the reader to quickly gauge a city's marketing and distribution value vis-à-vis others. This exercise is quite useful for persons setting up distribution centers or sales force strategies. Using econometric models which project fundamental economic dynamics within each region and city of influence, latent demand estimates are created for biosimilars. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of biosimilars as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include 3S Bio, AbbVie, Allergan, AMEGA Biotech, Amgen, Apotex, BIOCAD, Biocon, Biogen, Biopartners, Bioton, Boehringer Ingelheim, Celltrion, Cinnagen, Coherus BioSciences, DM Bio, Dr. Reddy`s Laboratories, Eli Lilly, Emcure Pharmaceuticals, EMD Serono, F. Hoffmann-La Roche, Fresenius Kabi, Fujifilm Diosynth Biotechnologies, Gedeon Richter, Genentech, Green Cross, Hanwa Chemical Corporation, Hospira, Intas Pharmaceuticals, JHL Biotech, LG Life Sciences, Mabxience, Merck, Mylan, Nanogen Biopharmaceutical, Neuclone, Novartis, Pfenex, Pfizer, Probiomed, RATIOPHARM GmbH, Roche Diagnostics, Samsung Bioepis, Sandoz, Shanghai Fosun Pharmaceutical, Stada Arzneimittel, Synthon Pharmaceuticals, Tanvex Biopharma, Teva Pharmaceutical Industries, and WOCKHARDT.. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

8/16/2022

This study covers the latent demand outlook for biopreservation across the regions of China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Chongqing, Shanghai, and Tianjin), special administrative regions (Hong Kong and Macau), and Taiwan (all hereafter referred to as "regions"). Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 1,100 cities in China. For each major city in question, the percent share the city is of the region and of China is reported. Each major city is defined as an area of "economic population", as opposed to the demographic population within a legal geographic boundary. For many cities, the economic population is much larger that the population within the city limits this is especially true for the cities of the Western regions. For the coastal regions, cities which are close to other major cities or which represent, by themselves, a high percent of the regional population, actual city-level population is closer to the economic population (e.g. in Beijing). Based on this "economic" definition of population, comparative benchmarks allow the reader to quickly gauge a city's marketing and distribution value vis-à-vis others. This exercise is quite useful for persons setting up distribution centers or sales force strategies. Using econometric models which project fundamental economic dynamics within each region and city of influence, latent demand estimates are created for biopreservation. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of biopreservation as including all commonly understood products falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include AMS BIOTECHNOLOGY (AMSBIO), Arctiko, Atlanta Biologicals, Avantor, BioCision, Biogenics, BioLife Solutions, BioLifeSolutions, Biomatrica, Bio-Techne, Cesca Therapeutics, Chart Industries, Core Dynamics, Ltd., Custom Biogenic Systems, Exact Sciences, Genzyme, Helmer Scientific, Labvantage Solutions, Lifeline Scientific, Merck KGaA, OPS Diagnostics, Organ Recovery Systems, Panasonic Corporation, PHC Holdings, Princeton CryoTech, Qiagen, SHANGHAI GENEXT Medical Technology Company, Ltd., Sigma, So-Low Environmental Equipment Company, STEMCELL Technologies, Taylor-Wharton, Teva Pharmaceuticals, Thermo Fisher Scientific, VWR, and Worthington Industries. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

8/16/2022

This study covers the latent demand outlook for biosimilars and follow-on biologics drugs across the regions of China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Chongqing, Shanghai, and Tianjin), special administrative regions (Hong Kong and Macau), and Taiwan (all hereafter referred to as "regions"). Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 1,100 cities in China. For each major city in question, the percent share the city is of the region and of China is reported. Each major city is defined as an area of "economic population", as opposed to the demographic population within a legal geographic boundary. For many cities, the economic population is much larger that the population within the city limits this is especially true for the cities of the Western regions. For the coastal regions, cities which are close to other major cities or which represent, by themselves, a high percent of the regional population, actual city-level population is closer to the economic population (e.g. in Beijing). Based on this "economic" definition of population, comparative benchmarks allow the reader to quickly gauge a city's marketing and distribution value vis-à-vis others. This exercise is quite useful for persons setting up distribution centers or sales force strategies. Using econometric models which project fundamental economic dynamics within each region and city of influence, latent demand estimates are created for biosimilars and follow-on biologics drugs. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of biosimilars and follow-on biologics drugs as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Allergan, Allozyne, Alteogen, Alvogen, Amarey Novamedical, AMEGA Biotech, Amgen, Apotex, Astellas Pharma, AstraZeneca, Avesthagen, Baxter, Bayer, Beijing Four Rings, BIOCAD, Bioceuticals, Biocon, Biogen, Biolab, Bionovis, Biopartners, Biosidus, Bioton, BioXpress Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Cambridge Antibody Technology, CCL Pharmaceuticals, CCM Duopharma, Celltrion, Centocor Ortho Biotech, Chong Kun Dang, Chugai, CinnaGen., Coherus BioSciences, Compass Biotechnologies, Cristália, CT Arzneimittel, Cyplasin, Daiichi Sankyo, Dong-A Pharmaceutical, Dr. Reddy’s Laboratories, Egis Pharmaceuticals, Eisai, Eli Lilly, Elpen Pharmaceutical, Emcure Pharmaceuticals, EMS, Epirus, Eurofarma, Express Scripts, FibroGen, Finox Biotech, Fuji Pharma, Gan & Lee, Genetech, Genexine, Gennova, GenSci, Genzyme, Geropharm, Gilead Sciences, GlaxoSmithKline, Hangzhou Jiuyuan Gene Engineering Company, Hanmi Pharmaceutical, Hanwha Chemical, Haselmeier, Health Canada, Helius Biotech, Hexal, Hindustan Antibiotic, Hospira, Hualida Biotech, Hypermarcas, IGES Institute, Intas Biopharmaceuticals, inVentiv Health, JCR Pharmaceuticals, Johnson & Johnson, Kabi, Kemwell Biopharma, Kissea, Koçak Farma, Kwizda Pharma, Kyowa Hakko Kirin, Landsteiner Scientific, LG Life Sciences, Libbs, LKM SA, Lonza Group, Mabion, Marvel Life Sciences, MEDICE Arzneimittel Pütter, Merck (MSD), Minapharm, Mitsubishi Tanabe, Mochida Pharmaceutical, Momenta Pharmaceuticals, Mycenax Biotech, Mylan, Nichi-Iko, Nippion Kayaku, Novartis, Novo Nordisk, Nuron Biotech, Oncobiologics, Ortho Pharmaceutical, Orygen, PanGen Biotech, Pfenex, Pfizer, Pharmapark, Pharmstandard, PRA International, Pro Generika, Qilu Pharmaceutical, Quintiles, Ranbaxy Laboratories, RAND Corporation, Ratiopharm, Regeneron Pharmaceuticals, Reliance GeneMedix, Rentschler Biotechnologie, Roche, Samsung Bioepis, Sandoz, Sanofi, SciGen, Shandong Kexing Pharma, Shanghai Celgen Biopharmaceutical, Shantha Biotechnics, Shinogi, Sicor Biotech, Sothema Laboratories, Spectrum Pharmaceuticals, Stada Arzneimittel, Stragen Pharma, Strides Arcolab, Syngene International, Synthon Biopharmaceuticals, Takeda, Teva, Tianjin Hualida Biotechnology, Tonghua Dongbao, TSH Biopharm, União Química, USV Biologics, Virchow Biotech, Wanbang Biopharmaceuticals, Wockhardt, Xiamen Amoytop Biotech, Zenotech, Zhejian Huahai Pharmaceutical, Zuventus, and Zydus Biovation. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

8/16/2022

This study covers the latent demand outlook for biophotonics across the regions of China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Chongqing, Shanghai, and Tianjin), special administrative regions (Hong Kong and Macau), and Taiwan (all hereafter referred to as "regions"). Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 1,100 cities in China. For each major city in question, the percent share the city is of the region and of China is reported. Each major city is defined as an area of "economic population", as opposed to the demographic population within a legal geographic boundary. For many cities, the economic population is much larger that the population within the city limits this is especially true for the cities of the Western regions. For the coastal regions, cities which are close to other major cities or which represent, by themselves, a high percent of the regional population, actual city-level population is closer to the economic population (e.g. in Beijing). Based on this "economic" definition of population, comparative benchmarks allow the reader to quickly gauge a city's marketing and distribution value vis-à-vis others. This exercise is quite useful for persons setting up distribution centers or sales force strategies. Using econometric models which project fundamental economic dynamics within each region and city of influence, latent demand estimates are created for biophotonics. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of biophotonics as including all commonly understood products falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Affymetrix, Andor Technology, BD (Becton, Dickinson and Company), Becton, BioTek Instruments, Carl Zeiss, Dickinson and Company, FEI Company, Hamamatsu Photonics, IDEX, IPG Photonics, Lumenis, Ocean Optics, Olympus America, Oxford Instruments, PerkinElmer, Toshiba, and Zecotek Photonic, Inc.. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

8/16/2022

This study covers the latent demand outlook for bipolar disorder treatments across the regions of China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Chongqing, Shanghai, and Tianjin), special administrative regions (Hong Kong and Macau), and Taiwan (all hereafter referred to as "regions"). Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 1,100 cities in China. For each major city in question, the percent share the city is of the region and of China is reported. Each major city is defined as an area of "economic population", as opposed to the demographic population within a legal geographic boundary. For many cities, the economic population is much larger that the population within the city limits this is especially true for the cities of the Western regions. For the coastal regions, cities which are close to other major cities or which represent, by themselves, a high percent of the regional population, actual city-level population is closer to the economic population (e.g. in Beijing). Based on this "economic" definition of population, comparative benchmarks allow the reader to quickly gauge a city's marketing and distribution value vis-à-vis others. This exercise is quite useful for persons setting up distribution centers or sales force strategies. Using econometric models which project fundamental economic dynamics within each region and city of influence, latent demand estimates are created for bipolar disorder treatments. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of bipolar disorder treatments as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include AbbVie, Allergan, Amneal Pharmaceutical, Aurobindo Pharma, Avet Pharmaceuticals, Currax Pharmaceuticals, Endo Pharmaceuticals, Johnson & Johnson, Lannett, Mallinckrodt, Mayne Pharma Group, Mylan NV, Novartis, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries, Wockhardt, and Zydus Cadila. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

8/16/2022

This study covers the latent demand outlook for biostimulants across the regions of China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Chongqing, Shanghai, and Tianjin), special administrative regions (Hong Kong and Macau), and Taiwan (all hereafter referred to as "regions"). Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 1,100 cities in China. For each major city in question, the percent share the city is of the region and of China is reported. Each major city is defined as an area of "economic population", as opposed to the demographic population within a legal geographic boundary. For many cities, the economic population is much larger that the population within the city limits this is especially true for the cities of the Western regions. For the coastal regions, cities which are close to other major cities or which represent, by themselves, a high percent of the regional population, actual city-level population is closer to the economic population (e.g. in Beijing). Based on this "economic" definition of population, comparative benchmarks allow the reader to quickly gauge a city's marketing and distribution value vis-à-vis others. This exercise is quite useful for persons setting up distribution centers or sales force strategies. Using econometric models which project fundamental economic dynamics within each region and city of influence, latent demand estimates are created for biostimulants. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of biostimulants as including all commonly understood products falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Acadian Seaplants, ADAMA, Agricen, Agriculture Solutions, Inc., Agrinos, Agroenzymas, Artal Agronutrients, Arysta LifeSceince, Atlantica Agricola, ATLÁNTICA AGRICOLA, Barndt Consolidated, BASF, Bayer, BioAg Alliance, BioAtlantis, Biolchim, Biostadt India, Biovert-Manvert, Brandt Consoliated, Cairochem, Corp., Eastman Chemical Company, Evergrow, FMC Corporation, Goemar, Haifa Group, Humic Growth, Ilsa, Isagro, Italpollina, Kelp Products International, Koppert, Laboratoires Goemar, Lallemand, LLSA, Micromix, Novozymes, OMEX, Platform Specialty Product, Premier Tech, SAPEC, Seipasa, Syngenta, Taminco, The DOW Chemical Company, Trade Corporation International, Tradeecorp Internationals, UPI, UPL, Valagro, and West Coast Marine Bio-Processing. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

8/16/2022

This study covers the latent demand outlook for biological imaging reagents across the regions of China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Chongqing, Shanghai, and Tianjin), special administrative regions (Hong Kong and Macau), and Taiwan (all hereafter referred to as "regions"). Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 1,100 cities in China. For each major city in question, the percent share the city is of the region and of China is reported. Each major city is defined as an area of "economic population", as opposed to the demographic population within a legal geographic boundary. For many cities, the economic population is much larger that the population within the city limits this is especially true for the cities of the Western regions. For the coastal regions, cities which are close to other major cities or which represent, by themselves, a high percent of the regional population, actual city-level population is closer to the economic population (e.g. in Beijing). Based on this "economic" definition of population, comparative benchmarks allow the reader to quickly gauge a city's marketing and distribution value vis-à-vis others. This exercise is quite useful for persons setting up distribution centers or sales force strategies. Using econometric models which project fundamental economic dynamics within each region and city of influence, latent demand estimates are created for biological imaging reagents. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of biological imaging reagents as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Bayer, Becton, Dickinson and Company, Bracco, GE Healthcare, Guerbet, Lantheus Holdings, Luminex Corporation, PerkinElmer, Siemens Healthineers, and Thermo Fisher Scientific. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

8/16/2022

This study covers the latent demand outlook for biologic vasculitis treatments across the regions of China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Chongqing, Shanghai, and Tianjin), special administrative regions (Hong Kong and Macau), and Taiwan (all hereafter referred to as "regions"). Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 1,100 cities in China. For each major city in question, the percent share the city is of the region and of China is reported. Each major city is defined as an area of "economic population", as opposed to the demographic population within a legal geographic boundary. For many cities, the economic population is much larger that the population within the city limits this is especially true for the cities of the Western regions. For the coastal regions, cities which are close to other major cities or which represent, by themselves, a high percent of the regional population, actual city-level population is closer to the economic population (e.g. in Beijing). Based on this "economic" definition of population, comparative benchmarks allow the reader to quickly gauge a city's marketing and distribution value vis-à-vis others. This exercise is quite useful for persons setting up distribution centers or sales force strategies. Using econometric models which project fundamental economic dynamics within each region and city of influence, latent demand estimates are created for biologic vasculitis treatments. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of biologic vasculitis treatments as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include AB Science, Acorda Therapeutics, Antares Pharma, Astellas Pharma, AstraZeneca, Baxter International, Boehringer Ingelheim International, Bristol-Myers Squibb, Can-Fite Biopharma, Celgene Corporation, Celltrion Healthcare Company, Coherus BioSciences, Daiichi Sankyo Company, Eisai Company, Eli Lilly and Company, F. Hoffmann-La Roche, Gilead Sciences, Inc., GlaxoSmithKline, Hospira, Idera Pharmaceuticals, Immunomedics, Incyte, Lexicon Pharmaceuticals, MedImmune, Merck & Company, Morphotek, Novartis, Novo Nordisk, Regeneron Pharmaceuticals, Sandoz International, Sanofi, Takeda Pharmaceutical Company, UCB, and Vertex Pharmaceuticals. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

8/16/2022

This study covers the latent demand outlook for biodegradable cutlery across the regions of China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Chongqing, Shanghai, and Tianjin), special administrative regions (Hong Kong and Macau), and Taiwan (all hereafter referred to as "regions"). Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 1,100 cities in China. For each major city in question, the percent share the city is of the region and of China is reported. Each major city is defined as an area of "economic population", as opposed to the demographic population within a legal geographic boundary. For many cities, the economic population is much larger that the population within the city limits this is especially true for the cities of the Western regions. For the coastal regions, cities which are close to other major cities or which represent, by themselves, a high percent of the regional population, actual city-level population is closer to the economic population (e.g. in Beijing). Based on this "economic" definition of population, comparative benchmarks allow the reader to quickly gauge a city's marketing and distribution value vis-à-vis others. This exercise is quite useful for persons setting up distribution centers or sales force strategies. Using econometric models which project fundamental economic dynamics within each region and city of influence, latent demand estimates are created for biodegradable cutlery. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of biodegradable cutlery as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include BETTER EARTH, LLC, Bionatic GmbH & Company, BioPak, Biotrem, Eco Guardian, Genpak, GreenGood USA, Huhtamäki, Pactiv, and vegware. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

8/16/2022

LATEST REPORTS

PRESS RELEASES

Use Code

SDMR20

Purchase any report

AVAIL FLAT DISCOUNT